
Experts determine the single factor which makes you most attractive to a potential partner... and it's NOT personality
The findings, published in the Journal of Marriage and Family, revealed that a higher bank balance could make you more attractive, signalling a sort of romantic readiness.
Researchers also found that people with higher incomes felt more ready to date and were more likely to actively look for a partner than those with less.
The Canadian researchers conducted two long-term studies—one in the US and the other in Germany—to see how people's relationship attitudes changed over time with their income.
In the US study, researchers specifically focused on 25-35-year olds, with the belief that this is when people are most likely to seek a relationship.
In both studies, results showed that single adults with higher incomes were more likely to say they felt it was the right time to find a partner.
When surveyed again, either six months or a year later, those who enjoyed bigger salaries were more likely to have found love.
In the German cohort, the effect was stronger for men than women though researchers said the bias was not significant.
Professor Geoff MacDonald, a relationship psychology expert from the University of Toronto, said: 'I think that young people are making rational calculations in unstable economic conditions.
'Young people understand they are not going to be able to enjoy a relationship if they are working 80 hours a week, of if they are not sure where they're going to live next year.'
Interestingly, earning more money or less money than the year before had little effect on whether people felt they were ready for a relationship.
What mattered most was financial stability, rather than short-term financial influx or decline.
Professor Johanna Peetz, study co-author and and personal spending expert, concluded that one reason for money and relationship desirability being so interconnected could be that money enables us to fulfil basic needs.
'With increasing financial resources higher hierarchical needs such as love and belonging—namely the intimacy and romance that are part of partnerships—might become more relevant.'
She added: 'This connection helps in understanding the sorts of tasks that many single people may be occupied with and organise their lives around, such as more firmly establishing material security.'
The researchers concluded that their findings should serve as a reminder to psychologists that whilst things like personality are important when it comes to forming and maintaining relationships, material conditions also play a significant role.
They added that their findings show that the role of income in relationship interest was largely similar in men and women, challenging the common perception that money in a primarily a concern in dating for men.
However, the researchers acknowledged that while the study provides evidence for a connection between wealth and relationship intentions, it does not prove that money causes people to enter into relationships.
They said a whole host of other factors including personality, life goals and cultural values, also play a role in romantic readiness.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
25 minutes ago
- Reuters
Siltronic posts Q2 revenue above expectations, cuts guidance
July 29 (Reuters) - German semiconductor materials supplier Siltronic ( opens new tab on Tuesday posted better-than-expected quarterly sales, but cut its annual sales guidance amid continued weakness in its semiconductor business and high customer inventories. The company posted second-quarter revenue of 329.1 million euros ($379.9 million), down from 351.3 million euros a year earlier. That was ahead of analysts' average forecast of 322 million euros according to a poll by LSEG. However, the group lowered its annual revenue expectations. It now expects sales to be in the mid-single-digit percentage range below the previous year, having previously guided towards sales being in the same region as the previous year. Shares in Siltronic, which have fallen 4% since the start of the year including today's session, were down 0.7% in early trading. In 2024, the company, which makes silicon wafers used in semiconductor chips, achieved revenue of 1.41 billion euros ($1.63 billion), which was 7% below the previous year. "The visible growth in end markets has so far not led to a normalization of inventory levels at chip manufacturers. As a result, there is still no noticeable recovery in demand at Siltronic," CEO Michael Heckmeier said in a statement. U.S. President Donald Trump's sweeping tariffs and uncertainty over his trade policies have sent global markets into a tailspin and significantly dampened investors' economic optimism. Analysts at Jefferies said in a note that the U.S. and European Union agreement still poses some questions on the potential impact on wafers. Siltronic confirmed its earnings before interest, taxes, depreciation and amortization margin target of between 21% and 25% for the year. ($1 = 0.8631 euros)


Reuters
an hour ago
- Reuters
European stocks rise amid earnings flurry, investors asses US-EU trade deal
July 29 (Reuters) - European equities edged higher on Tuesday, lifted by gains in EssilorLuxottica amid a slew of corporate results, while investors also assessed the implications of the newly signed trade pact between Washington and Brussels. The pan-European STOXX 600 index (.STOXX), opens new tab gained 0.3% by 0715 GMT. Most regional bourses also traded higher, with Germany's DAX (.GDAXI), opens new tab and France's CAC (.FCHI), opens new tab adding 0.5% each. The benchmark STOXX 600 rose 0.9% to hit a four-month high early in Monday's session but reversed course to close about 0.2% lower, as investors weighed the impact of a new 15% levy on most European Union goods, which is significantly higher than pre-2025 levels. Among individual stocks, Franco-Italian eyewear group EssilorLuxottica ( opens new tab shares jumped 5.4% after the company reported an increase in first-half operating profit despite a tariff hit. Dutch company Philips ( opens new tab rose almost 9% to the top of the index after the healthcare technology group lowered its tariff impact estimates following the U.S.-EU trade deal. On the flipside, car distributor Inchcape (INCH.L), opens new tab dropped 6.3% and ranked as the top decliner after posting a first-half profit drop due to tariff impact.


Reuters
an hour ago
- Reuters
AstraZeneca beats profit expectations on robust drug sales, U.S. demand
July 29 (Reuters) - AstraZeneca (AZN.L), opens new tab beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from President Donald Trump. The beat is a boost for the drugmaker as the wider sector braces for U.S. tariffs on pharmaceutical imports and navigates pricing challenges after Trump's order pushing for prices in the U.S. to fall to what other countries pay. The firm's shares rose around 1% in early trading on Tuesday. AstraZeneca, the UK's largest-listed company by market value, in April had forecast only a limited impact from potential U.S. tariffs on pharmaceutical imports, and said it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-U.S. trade deal over the weekend will result in a 15% tariff on pharmaceuticals from the region. The Anglo-Swedish drugmaker, which is targeting $80 billion in annual revenue by 2030, maintained its annual outlook and increased its interim dividend by 3%. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said in a statement. Sales of AstraZeneca's oncology drugs, which make up nearly half of its revenue and are being weighed down by changes in U.S. Medicare price negotiations, were up 18% at $6.31 billion at constant currency rates for the three-month period ended June 30. Analysts at Jefferies said sales of key cancer drugs such as Tagrisso, Lynparza, Calquence, and Truqap and Imfinzi were ahead of expectations. Total revenue grew 11% to $14.46 billion, with core earnings of $2.17 per share, with double-digit growth in the U.S., which makes up more than 40% of sales. That compares with analysts' expectations of $14.15 billion and $2.16, respectively, according to a company-provided consensus. AstraZeneca, which is hoping to move on from scandals in its second-biggest market, China, where it also faces minor fines related to cancer drugs, said it was also fighting several patent challenges from an individual against Tagrisso.